Evidence map›Paper›PMID 36918874›Full record

ArticleJournal of nanobiotechnology2023

Combination therapy based on dual-target biomimetic nano-delivery system for overcoming cisplatin resistance in hepatocellular carcinoma.

Yufen Huang, Qinjie Kou, Yanrong Su, Lu Lu, Xisheng Li, Haiye Jiang, Rong Gui, Rong Huang, Xinmin Nie, Jian Li

Open access · goldFull text read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of nanobiotechnology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
5.8field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 38 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Review
  13. Article
  14. Review
  15. Non-coding RNA and drug resistance in head and neck cancer.Cancer drug resistance (Alhambra, Calif.) · 2024
    Review
  16. Review
  17. Article
  18. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Yufen HuangDepartment of Laboratory Medicine, Third Xiangya Hospital, Central South University, Changsha, 410013, Hunan, China.
Qinjie KouDepartment of Laboratory Medicine, Third Xiangya Hospital, Central South University, Changsha, 410013, Hunan, China.
Yanrong SuDepartment of Laboratory Medicine, Third Xiangya Hospital, Central South University, Changsha, 410013, Hunan, China.
Lu LuDepartment of Blood Transfusion, Third Xiangya Hospital, Central South University, Changsha, 410013, Hunan, China.
Xisheng LiDepartment of Laboratory Medicine, Third Xiangya Hospital, Central South University, Changsha, 410013, Hunan, China.
Haiye JiangDepartment of Laboratory Medicine, Third Xiangya Hospital, Central South University, Changsha, 410013, Hunan, China.
Rong GuiDepartment of Blood Transfusion, Third Xiangya Hospital, Central South University, Changsha, 410013, Hunan, China.
Rong HuangDepartment of Blood Transfusion, Third Xiangya Hospital, Central South University, Changsha, 410013, Hunan, China.
Xinmin NieDepartment of Laboratory Medicine, Third Xiangya Hospital, Central South University, Changsha, 410013, Hunan, China. niexinmin@csu.edu.cn.
Jian LiDepartment of Blood Transfusion, Third Xiangya Hospital, Central South University, Changsha, 410013, Hunan, China. 603196@csu.edu.cn.
Central South University · CNEducation Department of Hunan Province · CNThird Xiangya Hospital · CN

Funding

Graduate Self Exploration and Innovation Project of Central South University of China under 2021zzts1084Graduate Self Exploration and Innovation Project of Central South University of China under 2022ZZTS0890National Natural Science Foundation of China 81971748National Natural Science Foundation of China 82001165Natural Science Foundation of Hunan Province 2020JJ4131Natural Science Foundation of Hunan Province 2021JJ31002Natural Science Foundation of Hunan Province 2021JJ40923Natural Science Foundation of Hunan Province 2021JJ40926Science and Technology Program of Hunan Province kh2201057the key research and development program of Hunan Province 2022SK2004 and 2020SK2111
6 · The paper itself

Abstract

Strategies to overcome toxicity and drug resistance caused by chemotherapeutic drugs for targeted therapy against hepatocellular carcinoma (HCC) are urgently needed. Previous studies revealed that high oxidored-nitro domain-containing protein 1(NOR1) expression in HCC was associated with cisplatin (DDP) resistance. Herein, a novel dual-targeting nanocarrier system AR-NADR was generated for the treatment of DDP resistance in HCC. The core of the nanocarrier system is the metal-organic frameworks (MOF) modified with nuclear location sequence (NLS), which loading with DDP and NOR1 shRNA (R). The shell is an A54 peptide inserted into the erythrocyte membrane (AR). Our results show that AR-NADR efficiently internalized by tumor cells due to its specific binding to the A54 receptors that are abundantly expressed on the surface of HCC cells and NLS peptide-mediated nuclear entry. Additionally, DDP is more likely to be released due to the degradation of Ag-MOF in the acidic tumor microenvironment. Moreover, by acting as a vector for gene delivery, AR-NADR effectively inhibits tumor drug resistance by suppressing the expression of NOR1, which induces intracellular DDP accumulation and makes cells sensitive to DDP. Finally, the anti-HCC efficacy and mechanisms of AR-NADR were systematically elucidated by a HepG2/DDP cell model as well as a tumor model. Therefore, AR-NADR constitutes a key strategy to achieve excellent gene silencing and antitumor efficacy, which provides effective gene therapy and precise treatment strategies for cisplatin resistance in HCC.

Indexed as

Antineoplastic AgentsCarcinoma, HepatocellularLiver NeoplasmsBiomimeticsCell Line, TumorCisplatinDrug Resistance, NeoplasmHumansTumor MicroenvironmentAntineoplastic AgentsCisplatinChemotherapyCisplatin resistanceDual-targetGene silencing

Identifiers

PMID36918874
PMCPMC10015699
OpenAlexW4324138688

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read88
table measurements read14
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.